CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

Dividend Growth: CVS has increased its dividend by 142% over the past decade, with a current forward yield of 4.64%. This significantly surpasses the S&P 500 average of 1.35%.

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Gilead Sciences agreed to make its hepatitis C medicines the exclusive treatments for CVS Health customers, intensifying a drug-industry rivalry to win patients for the $1,000-a-day medicines.

The battle for supremacy in one of the fastest-growing pharmaceutical markets intensified on Monday, with CVS Health Corp. saying it will make Gilead Sciences Inc.’s drugs Sovaldi and Harvoni ...

CVS to Exclusively Distribute Gilead Sciences's $1,000-Per-Pill Hepatitis C Treatment Published Jan 06, 2015 at 5:02 PM EST Updated Mar 12, 2016 at 9:16 AM EST ...